Health Catalyst (HCAT)
Market Price (5/2/2026): $1.56 | Market Cap: $110.8 MilSector: Health Care | Industry: Health Care Technology
Health Catalyst (HCAT)
Market Price (5/2/2026): $1.56Market Cap: $110.8 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -48% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Health Data Analytics, and AI in Healthcare Management. | Weak multi-year price returns2Y Excs Rtn is -118%, 3Y Excs Rtn is -166% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.51, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -43 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -14% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 73% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 141x Weak revenue growthRev Chg QQuarterly Revenue Change % is -6.2% Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6.7% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -177% Key risksHCAT key risks include [1] its struggle to achieve profitability, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -48% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Health Data Analytics, and AI in Healthcare Management. |
| Weak multi-year price returns2Y Excs Rtn is -118%, 3Y Excs Rtn is -166% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.51, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -43 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -14% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 73% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 141x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -6.2% |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6.7% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -177% |
| Key risksHCAT key risks include [1] its struggle to achieve profitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Stock Movement Drivers
Fundamental Drivers
The -32.6% change in HCAT stock from 1/31/2026 to 5/1/2026 was primarily driven by a -30.9% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5012026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.15 | 1.45 | -32.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 316 | 311 | -1.6% |
| P/S Multiple | 0.5 | 0.3 | -30.9% |
| Shares Outstanding (Mil) | 70 | 71 | -0.9% |
| Cumulative Contribution | -32.6% |
Market Drivers
1/31/2026 to 5/1/2026| Return | Correlation | |
|---|---|---|
| HCAT | -32.6% | |
| Market (SPY) | 3.6% | 24.1% |
| Sector (XLV) | -5.8% | -3.7% |
Fundamental Drivers
The -55.1% change in HCAT stock from 10/31/2025 to 5/1/2026 was primarily driven by a -53.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5012026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.23 | 1.45 | -55.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 316 | 311 | -1.6% |
| P/S Multiple | 0.7 | 0.3 | -53.5% |
| Shares Outstanding (Mil) | 70 | 71 | -1.9% |
| Cumulative Contribution | -55.1% |
Market Drivers
10/31/2025 to 5/1/2026| Return | Correlation | |
|---|---|---|
| HCAT | -55.1% | |
| Market (SPY) | 5.5% | 32.7% |
| Sector (XLV) | 1.5% | 8.0% |
Fundamental Drivers
The -63.3% change in HCAT stock from 4/30/2025 to 5/1/2026 was primarily driven by a -58.8% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5012026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.95 | 1.45 | -63.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 307 | 311 | 1.5% |
| P/S Multiple | 0.8 | 0.3 | -58.8% |
| Shares Outstanding (Mil) | 62 | 71 | -12.1% |
| Cumulative Contribution | -63.3% |
Market Drivers
4/30/2025 to 5/1/2026| Return | Correlation | |
|---|---|---|
| HCAT | -63.3% | |
| Market (SPY) | 30.4% | 35.1% |
| Sector (XLV) | 5.2% | 15.0% |
Fundamental Drivers
The -88.5% change in HCAT stock from 4/30/2023 to 5/1/2026 was primarily driven by a -86.5% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5012026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.60 | 1.45 | -88.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 276 | 311 | 12.6% |
| P/S Multiple | 2.5 | 0.3 | -86.5% |
| Shares Outstanding (Mil) | 54 | 71 | -24.1% |
| Cumulative Contribution | -88.5% |
Market Drivers
4/30/2023 to 5/1/2026| Return | Correlation | |
|---|---|---|
| HCAT | -88.5% | |
| Market (SPY) | 78.7% | 35.9% |
| Sector (XLV) | 14.3% | 25.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HCAT Return | -9% | -73% | -13% | -24% | -66% | -48% | -97% |
| Peers Return | 51% | 6% | 17% | 0% | -4% | -8% | 65% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| HCAT Win Rate | 42% | 25% | 50% | 42% | 8% | 0% | |
| Peers Win Rate | 67% | 47% | 57% | 48% | 50% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HCAT Max Drawdown | -16% | -84% | -37% | -41% | -71% | -58% | |
| Peers Max Drawdown | -4% | -20% | -11% | -21% | -36% | -26% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: UNH, ORCL, IQV, MCK, EVH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/1/2026 (YTD)
How Low Can It Go
| Event | HCAT | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.3% | -6.7% |
| % Gain to Breakeven | 41.5% | 7.1% |
| Time to Breakeven | 82 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -42.2% | -33.7% |
| % Gain to Breakeven | 73.1% | 50.9% |
| Time to Breakeven | 94 days | 140 days |
In The Past
Health Catalyst's stock fell -6.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 6.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | HCAT | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.3% | -6.7% |
| % Gain to Breakeven | 41.5% | 7.1% |
| Time to Breakeven | 82 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -42.2% | -33.7% |
| % Gain to Breakeven | 73.1% | 50.9% |
| Time to Breakeven | 94 days | 140 days |
In The Past
Health Catalyst's stock fell -6.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 6.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Health Catalyst (HCAT)
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Health Catalyst (HCAT):
- Snowflake for healthcare data
- Palantir for hospitals
AI Analysis | Feedback
```html- Cloud-based Data Platform: A foundational technology that aggregates, organizes, and manages diverse healthcare data for insights and decision-making.
- Analytics Software: Applications and tools designed to analyze healthcare data, providing actionable insights for clinical, financial, and operational improvements.
- Professional Services: Expert consulting and support engagements to assist healthcare organizations with implementing, optimizing, and leveraging their data and analytics solutions.
AI Analysis | Feedback
Health Catalyst (HCAT) primarily sells its data and analytics technology and services to healthcare organizations. These customers typically include large health systems, hospitals, academic medical centers, and payer organizations across the United States.
Given that most major U.S. health systems and hospitals are not publicly traded entities (many are non-profit or privately held), it is challenging to provide a list of "major customers" with associated public company stock symbols. Health Catalyst serves a broad and diverse client base rather than being reliant on a few publicly traded "major" customers.
However, based on public announcements, press releases, and case studies, examples of healthcare organizations that have utilized Health Catalyst's solutions include:
- Memorial Hermann Health System: A large not-for-profit health system based in Houston, Texas. (Not publicly traded)
- Rush University Medical Center: A major academic medical center in Chicago, Illinois. (Not publicly traded)
- UNC Health: A not-for-profit integrated healthcare system associated with the University of North Carolina. (Not publicly traded)
- Hartford HealthCare: An integrated healthcare system in Connecticut. (Not publicly traded)
- Banner Health: One of the largest secular non-profit healthcare systems in the country, based in Phoenix, Arizona. (Not publicly traded)
Health Catalyst's business model involves providing solutions to a wide array of healthcare organizations, and its customer relationships may vary and evolve over time. The company's revenue is generally diversified across numerous health systems rather than being concentrated in a few publicly listed entities.
AI Analysis | Feedback
```html
Amazon.com, Inc. (AMZN)
Microsoft Corporation (MSFT)
AI Analysis | Feedback
Ben Albert, Chief Executive Officer
Ben Albert was appointed CEO of Health Catalyst in February 2026. He joined Health Catalyst in January 2025 following the company's acquisition of Upfront Healthcare Services, where he served as CEO and Co-Founder. An experienced entrepreneur, Mr. Albert has spent over 25 years building and leading healthcare organizations. Prior to Upfront Healthcare, he founded and led Care Team Connect, a care management platform that was acquired by The Advisory Board Company in 2013. He also held executive positions at PatientKeeper, Inc., and Data Harbor, Inc., both of which were acquired. Mr. Albert also served as an Entrepreneur-in-Residence and Operating Partner within the Strategic Investments Division of Cambia Health Solutions.
Jason Alger, Chief Financial Officer
Jason Alger became the Chief Financial Officer of Health Catalyst on March 1, 2024. He joined Health Catalyst in April 2013 and previously served as the company's Chief Accounting Officer since January 2021 and Senior Vice President of Finance since September 2017. Prior to his tenure at Health Catalyst, Mr. Alger worked in the assurance practice at the public accounting firm Ernst & Young LLP from August 2009 to April 2013. He is a Certified Public Accountant and holds a Master of Accountancy degree from Brigham Young University.
Holly Rimmasch, Senior Vice President and Chief Clinical Officer
Holly Rimmasch serves as the Chief Clinical Officer and SVP & GM, Clinical Quality Business Unit at Health Catalyst. She brings over three decades of healthcare experience, including direct patient care, clinical and operational healthcare strategy, and management. Before joining Health Catalyst, she held roles such as Assistant VP at Intermountain Healthcare, where she was responsible for Clinical Services. Ms. Rimmasch also co-founded and was a Principal in HMS, Inc., a healthcare strategic consulting firm focused on population health.
Linda Llewelyn, Chief People Officer
Linda Llewelyn is the Chief People Officer at Health Catalyst, having joined the company in June 2013 as an HR Manager. Before her time at Health Catalyst, she worked in various HR leadership capacities across several industries, including medical technology, healthcare, and financial services, with companies such as Fairchild Semiconductor, BD Medical, Discover Financial Services, Morgan Stanley, and UnitedHealth Group. She has a Bachelor's Degree in Psychology from the University of Utah.
TJ Elbert, Senior Vice President, Chief Data Officer, and General Manager of the Data Platform Business Unit
TJ Elbert joined Health Catalyst in January 2019 and holds the positions of Senior Vice President, Chief Data Officer, and General Manager of the Data Platform Business Unit. He brings over 15 years of experience in healthcare information technology, data warehousing, and analytics. Before Health Catalyst, Mr. Elbert held various leadership roles in data warehousing and population health at Northwestern Medicine. He also worked as an Integration Architect at Cerner Corporation, leading EMR implementations and services engagements.
AI Analysis | Feedback
The key risks to Health Catalyst (HCAT) are as follows:- Profitability and Financial Health: Health Catalyst has consistently faced challenges in achieving profitability, reporting significant net losses and negative operating margins. The company's financial performance has shown declining revenue growth, with analysts expecting continued revenue decline in the coming years. Furthermore, its Altman Z-Score places the company in a distress zone, suggesting a potential risk of bankruptcy.
- Intense Competition and Market Position: The healthcare technology market in which Health Catalyst operates is highly competitive and fragmented. The company faces formidable competition from larger entities such as Oracle (through its Cerner acquisition) and Epic Systems, which possess vast resources and entrenched customer relationships. These larger competitors can offer bundled analytics solutions with their core Electronic Health Record (EHR) offerings, creating significant pricing pressure and making it challenging for Health Catalyst, as a smaller, specialized player, to demonstrate sufficient return on investment for its separate solutions.
- Platform Migration Challenges and Revenue Headwinds: Health Catalyst is currently undertaking a strategic migration from its older Data Operating System (DOS) platform to its newer Ignite platform. This transition has resulted in substantial revenue headwinds, including "downsell" and "churn" of Annual Recurring Revenue (ARR) and a portion of ARR being subject to negotiation. This ongoing migration is contributing to near-term revenue volatility and has led to reduced revenue guidance.
AI Analysis | Feedback
The increasing maturation and direct competition from major cloud providers (e.g., Amazon Web Services with HealthLake, Microsoft Azure with Microsoft Cloud for Healthcare, Google Cloud Platform with its Healthcare API) offering integrated, HIPAA-compliant data platforms and advanced analytics services specifically tailored for healthcare organizations. These providers possess vast resources, existing enterprise relationships, and can offer a seamless, vertically integrated stack from infrastructure to specialized healthcare analytics, potentially disintermediating specialized third-party data and analytics providers like Health Catalyst.
AI Analysis | Feedback
Health Catalyst, Inc. (HCAT) operates within several large and growing addressable markets in the healthcare sector, primarily focusing on data and analytics technology and services. The company's main products and services encompass cloud-based data platforms, analytics software, and professional services.
Addressable Markets for Health Catalyst's Products and Services:
Healthcare Cloud Computing Market (relevant to cloud-based data platform)
- The global healthcare cloud computing market was valued at approximately USD 19.6 billion in 2023 and is projected to reach USD 45.1 billion by 2030, with a compound annual growth rate (CAGR) of 12.7% from 2024 to 2030.
- Other estimates place the global healthcare cloud computing market size at USD 63.55 billion in 2025, with a projection to grow to USD 251.15 billion by 2034 at a CAGR of 16.40% from 2026 to 2034.
- Another report indicates the market size was USD 63.9 billion in 2025 and is predicted to increase to approximately USD 312.97 billion by 2035, expanding at a CAGR of 17.22% from 2026 to 2035.
- North America dominated the global healthcare cloud computing market in 2023, holding a share of 44.1%, with the U.S. market being the largest within this region. North America is also reported to have dominated the market with a 39.60% share in 2025 and a 41% share in 2025.
Healthcare Analytics Market (relevant to analytics software)
- The global healthcare analytics market was valued at USD 30.33 billion in 2025. It is projected to grow from USD 36.03 billion in 2026 to USD 262.52 billion by 2034, exhibiting a CAGR of 28.18% during the forecast period.
- Another assessment states the market size at USD 57.16 billion in 2025, expected to reach USD 70.00 billion in 2026 and USD 192.78 billion by 2031, reflecting a 22.46% CAGR.
- The global healthcare big data analytics market, a closely related segment, was valued at USD 52.1 billion in 2025 and is estimated to reach USD 130.2 billion by 2034, growing at a CAGR of 10.72% from 2026 to 2034.
- North America held the largest share of the healthcare analytics market, accounting for 49.03% in 2025. For big data analytics in healthcare, North America dominated with over 52% market share in 2024.
Healthcare Consulting Services Market (relevant to professional services)
- The global healthcare consulting services market was estimated at USD 28.19 billion in 2023 and is projected to reach USD 51.98 billion by 2030, growing at a CAGR of 9.33% from 2024 to 2030.
- Other data suggests the market size was USD 34.53 billion in 2025 and is estimated to grow from USD 37.58 billion in 2026 to reach USD 57.34 billion by 2031, at a CAGR of 8.83%.
- Another report indicates the market size was calculated at USD 36.44 billion in 2025 and is predicted to increase to approximately USD 79.41 billion by 2035, expanding at a CAGR of 8.10% from 2026 to 2035.
- North America dominated the healthcare consulting services market with a share of 38.14% in 2023 and 40.3% in 2024.
AI Analysis | Feedback
Health Catalyst (HCAT) anticipates future revenue growth over the next two to three years driven by several strategic initiatives:
- Advancement and Migration to Health Catalyst Ignite Platform with Enhanced AI Capabilities: The company is focused on migrating clients to its next-generation, multi-tenant Health Catalyst Ignite platform, which is enabled by Snowflake and Databricks. This platform is central to advancing AI capabilities within its offerings, aiming to drive long-term improvement and scalability for clients.
- Expansion into Higher-Margin Technology Solutions: Health Catalyst is strategically shifting its focus towards higher-margin technology solutions and high-value client contracts. This includes an emphasis on growing recurring revenue from its technology segment, which has demonstrated consistent year-over-year growth.
- Acquisition and Retention of New Clients, Alongside Expanding Existing Relationships: A key driver is the continued acquisition of new clients, referred to as "net new DOS Subscription client additions" and "net new logos." The company also aims to expand its revenue from the existing customer base through a strong dollar-based retention rate, fostering long-term partnerships and innovations.
- Strategic Acquisitions to Enhance Service Offerings: Health Catalyst leverages strategic acquisitions to expand its portfolio and market reach. A notable example is the acquisition of Intraprise Health, which strengthened the company's cybersecurity offerings, thereby creating new revenue streams and opportunities for growth.
AI Analysis | Feedback
Share Repurchases
- Health Catalyst's board of directors approved a share repurchase program on August 2, 2022, authorizing the purchase of up to $40 million of its common stock.
- Approximately $5 million of common stock was repurchased between March 3, 2025, and March 10, 2025.
Share Issuance
- Securities were offered to employees through benefit plans as indicated in an S-8 SEC filing on March 12, 2026.
Outbound Investments
- Health Catalyst completed the acquisition of Upfront Healthcare for $86 million in January 2025, enhancing its data analytics platform to aid clinics in scheduling and resource allocation.
- The company acquired Lumeon in August 2024, a digital health company specializing in automated care orchestration, funded through a mix of stock and cash.
- Health Catalyst acquired Intraprise Health in November 2024, a cybersecurity provider, with the transaction funded by a combination of cash and stock.
Capital Expenditures
- Health Catalyst's trailing twelve months (TTM) capital expenditure average over three years was $15.4 million.
- Over the past five years, the average capital expenditure average over three years has been $14.27 million.
- Capital expenditures were reported as -$1.11 million in the last 12 months.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Health Catalyst Earnings Notes | 12/16/2025 | |
| Would You Still Hold Health Catalyst Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to HCAT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 164.80 |
| Mkt Cap | 63.5 |
| Rev LTM | 40,194 |
| Op Inc LTM | 4,078 |
| FCF LTM | 1,028 |
| FCF 3Y Avg | 963 |
| CFO LTM | 6,568 |
| CFO 3Y Avg | 3,996 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.8% |
| Rev Chg 3Y Avg | 10.8% |
| Rev Chg Q | 10.8% |
| QoQ Delta Rev Chg LTM | 2.7% |
| Op Inc Chg LTM | 8.7% |
| Op Inc Chg 3Y Avg | 10.2% |
| Op Mgn LTM | 2.9% |
| Op Mgn 3Y Avg | 4.2% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 3.5% |
| CFO/Rev 3Y Avg | 4.7% |
| FCF/Rev LTM | 1.3% |
| FCF/Rev 3Y Avg | 1.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 63.5 |
| P/S | 0.5 |
| P/Op Inc | 14.4 |
| P/EBIT | 14.4 |
| P/E | 21.4 |
| P/CFO | 13.9 |
| Total Yield | 4.6% |
| Dividend Yield | 0.2% |
| FCF Yield 3Y Avg | 3.1% |
| D/E | 0.5 |
| Net D/E | 0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 21.9% |
| 3M Rtn | 1.4% |
| 6M Rtn | -30.6% |
| 12M Rtn | -0.5% |
| 3Y Rtn | -17.9% |
| 1M Excs Rtn | 11.9% |
| 3M Excs Rtn | -2.8% |
| 6M Excs Rtn | -37.3% |
| 12M Excs Rtn | -32.9% |
| 3Y Excs Rtn | -96.2% |
Price Behavior
| Market Price | $1.45 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 07/25/2019 | |
| Distance from 52W High | -67.9% | |
| 50 Days | 200 Days | |
| DMA Price | $1.39 | $2.46 |
| DMA Trend | down | down |
| Distance from DMA | 4.7% | -41.1% |
| 3M | 1YR | |
| Volatility | 96.5% | 75.3% |
| Downside Capture | 1.93 | 1.44 |
| Upside Capture | 96.03 | 70.72 |
| Correlation (SPY) | 24.3% | 34.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.18 | 0.94 | 1.49 | 1.91 | 2.07 | 1.59 |
| Up Beta | 1.10 | 0.70 | 0.98 | 2.89 | 3.13 | 1.59 |
| Down Beta | -13.24 | -0.97 | 0.19 | 1.01 | 1.63 | 1.64 |
| Up Capture | 109% | 85% | 96% | 55% | 61% | 75% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 10 | 19 | 26 | 49 | 101 | 335 |
| Down Capture | -11% | 215% | 266% | 219% | 181% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 12 | 22 | 35 | 73 | 140 | 401 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HCAT | |
|---|---|---|---|---|
| HCAT | -62.4% | 75.3% | -0.97 | - |
| Sector ETF (XLV) | 5.2% | 16.0% | 0.13 | 14.8% |
| Equity (SPY) | 30.6% | 12.5% | 1.88 | 35.0% |
| Gold (GLD) | 39.5% | 27.2% | 1.20 | -3.5% |
| Commodities (DBC) | 51.5% | 17.9% | 2.20 | -1.7% |
| Real Estate (VNQ) | 13.1% | 13.5% | 0.67 | 17.8% |
| Bitcoin (BTCUSD) | -18.2% | 42.1% | -0.36 | 20.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HCAT | |
|---|---|---|---|---|
| HCAT | -51.5% | 67.3% | -0.78 | - |
| Sector ETF (XLV) | 5.0% | 14.6% | 0.17 | 30.6% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 42.2% |
| Gold (GLD) | 20.5% | 17.9% | 0.94 | 4.4% |
| Commodities (DBC) | 14.3% | 19.1% | 0.61 | 5.8% |
| Real Estate (VNQ) | 3.5% | 18.8% | 0.09 | 36.5% |
| Bitcoin (BTCUSD) | 7.4% | 56.1% | 0.35 | 19.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HCAT | |
|---|---|---|---|---|
| HCAT | -27.9% | 65.3% | -0.46 | - |
| Sector ETF (XLV) | 9.1% | 16.5% | 0.45 | 30.5% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 39.6% |
| Gold (GLD) | 13.6% | 15.9% | 0.71 | 5.5% |
| Commodities (DBC) | 9.7% | 17.7% | 0.46 | 10.2% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 33.0% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.07 | 19.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/12/2026 | -26.3% | -32.1% | -40.8% |
| 11/10/2025 | -5.6% | -21.4% | -10.2% |
| 5/7/2025 | 5.3% | 5.3% | 3.3% |
| 2/26/2025 | -11.1% | -7.9% | -6.9% |
| 8/7/2024 | 37.8% | 15.3% | 33.0% |
| 5/9/2024 | -3.9% | 5.4% | 0.1% |
| 10/27/2023 | 1.2% | 8.7% | 9.4% |
| 8/8/2023 | -3.8% | -1.9% | -8.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 10 |
| # Negative | 13 | 13 | 11 |
| Median Positive | 3.6% | 7.0% | 6.1% |
| Median Negative | -5.4% | -7.9% | -8.4% |
| Max Positive | 37.8% | 68.8% | 69.1% |
| Max Negative | -37.9% | -32.1% | -40.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Total Revenue | 68.00 Mil | 69.00 Mil | 70.00 Mil | ||||
| Q1 2026 Adjusted EBITDA | 7.00 Mil | 7.50 Mil | 8.00 Mil | ||||
Prior: Q4 2025 Earnings Reported 1/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 310.00 Mil | 0 | Affirmed | Guidance: 310.00 Mil for 2025 | |||
| 2025 Adj. EBITDA | 41.00 Mil | 0 | Affirmed | Guidance: 41.00 Mil for 2025 | |||
| 2025 Net new Platform Clients | 30 | Affirmed | |||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Landry, Benjamin | General Counsel | Direct | Sell | 12082025 | 2.64 | 27,425 | 72,328 | 263,730 | Form |
| 2 | Larson-Green, Julie | Direct | Sell | 12082025 | 2.67 | 47,997 | 128,349 | 196,742 | Form | |
| 3 | Landry, Benjamin | General Counsel | Direct | Sell | 9092025 | 3.35 | 6,175 | 20,705 | 475,496 | Form |
| 4 | Landry, Benjamin | General Counsel | Direct | Sell | 6092025 | 3.94 | 6,057 | 23,891 | 596,082 | Form |
| 5 | Lesueur, Daniel | Chief Operating Officer | Direct | Sell | 5072025 | 4.10 | 5,209 | 21,331 | 842,903 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.